Drug Trial Radar · NCT06538857
CEB-01 in Locally Resectable Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
39
Planned (sponsor's estimate)
Start
Aug 20, 2024
Primary completion
Sep 2028
Study completion Sep 2028
Sponsor
- Lead sponsor
- CEBIOTEXIndustry
- Sponsor type
- Industry
- Collaborators
- MFAR
- First posted
- Aug 6, 2024
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The CEB-01 implant is a membrane containing SN-38, the active metabolite of irinotecan, an already authorized chemotherapeutic agent. After surgical removal of the pancreatic cancer tumor, CEB 01 will be placed in the surgical bed for a local and sustained release of the chemotherapy. This is expected to delay or prevent local recurrence of pancreatic cancer after surgery, while keeping a tolerable toxicity profile. The study aims to assess the safety, tolerability, pharmacokinetics, and efficacy of CEB-01 in patients with locally resectable pancreatic cancer
Conditions
- Pancreatic Carcinoma
Interventions
Standard surgeryProcedure
The location and size of the tumor determine the type of surgery.
CEB-01Drug
It is novel formulation for local release of chemotherapy. It consists of a biocompatible and biodegradable nanofiber membrane made of poly(lactic-co-glycolic acid) (PLGA), which is loaded with the anti-tumor drug SN-38 and implanted in the surgical bed after tumor removal.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of Adverse Events (AEs) (Safety)Time frame: Through study completion, average 3 years
- Frequency of surgical complications after pancreatic surgeryTime frame: Through study completion, after surgery average 3 years
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Hospital Clínico y Provincial de Barcelona
Barcelona, Catalonia, Spain
H. Clínico San Carlos
Madrid, Madrid, Spain
H.U. Virgen del Rocío
Seville, Sevilla, Spain
H. Clínico Univ. de Valencia
Valencia, Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.